Vanda Pharmaceuticals (VNDA) announced that Nereus is now commercially available across the United States for the prevention of vomiting induced by motion in adults.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNDA:
- Vanda Pharmaceuticals Adds Independent Director to Strengthen Board
- AnaptysBio price target lowered to $60 from $90 at UBS
- Geron appoints Timothy Williams as chief legal officer
- Vanda calls on FDA to remove proposal extending drug review timelines
- Vanda Pharmaceuticals: Undervalued GLP-1 Adjunct Opportunity Driven by Tradipitant’s Pivotal Thetis Trial